<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993261</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0578</org_study_id>
    <secondary_id>NCI-2019-02477</secondary_id>
    <secondary_id>2014-0578</secondary_id>
    <nct_id>NCT04993261</nct_id>
  </id_info>
  <brief_title>An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors</brief_title>
  <official_title>Evaluation of Dual Energy CT for the Detection of Gastrointestinal Carcinoids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the use of a special type of computed (CT) scan called dual energy CT in&#xD;
      detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and&#xD;
      a computer to create images of areas inside the body. Dual energy computed tomography is a&#xD;
      technique used during routine CT scans to help obtain and process the image after the scan is&#xD;
      complete. Doctors want to learn if dual energy computed tomography can help improve the&#xD;
      detection of carcinoid tumors during routine CT scans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Evaluate prospectively the sensitivity and specificity of dual energy computed tomography&#xD;
      (CT) in detecting primary gastrointestinal (GI) carcinoid.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo one dual energy CT scan during scheduled CT scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 23, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity of dual energy computed tomography in detecting primary gastrointestinal carcinoid tumors</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Carcinoid Syndrome</condition>
  <condition>Carcinoid Tumor</condition>
  <condition>Digestive System Neuroendocrine Tumor G1</condition>
  <condition>Metastatic Carcinoid Tumor</condition>
  <arm_group>
    <arm_group_label>Diagnostic (dual energy CT scan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo one dual energy CT scan during scheduled CT scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Dual-Energy Computed Tomography</intervention_name>
    <description>Undergo dual energy CT scan</description>
    <arm_group_label>Diagnostic (dual energy CT scan)</arm_group_label>
    <other_name>DECT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with: clinical features of carcinoid syndrome (or) increased serum and&#xD;
             urinary markers suggestive of carcinoid (or) endoscopic biopsy proven carcinoid (or)&#xD;
             metastases which are biopsy proven as carcinoid.&#xD;
&#xD;
          -  Patient is scheduled to have a clinically indicated staging CT exam.&#xD;
&#xD;
          -  Patients who have signed their informed consent form to undergo the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have already had their primary GI carcinoid resected.&#xD;
&#xD;
          -  Contraindication to intravenous contrast agents (e.g. allergy, renal failure,&#xD;
             dialysis, pregnancy etc.).&#xD;
&#xD;
          -  Pregnant patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Kundra</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Kundra</last_name>
      <phone>713-745-2702</phone>
      <email>vkundra@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Vikas Kundra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 21, 2021</study_first_submitted>
  <study_first_submitted_qc>July 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

